2024
The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
Lee A, Runcie K, Yu J. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer 2024, 8: 45-50. DOI: 10.3233/kca-230020.Peer-Reviewed Original ResearchStereotactic body radiotherapyTreatment of renal cell carcinomaRenal cell carcinomaCell carcinomaCombination of stereotactic body radiotherapyUse of stereotactic body radiotherapyNovel systemic agentsTargeted radiation therapyTreatment of RCCRadiation therapySystemic agentsCarcinomaTreatmentRCCRadiotherapyRadiation technologyIncreased useTherapy
2022
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal Of Neurosurgery 2022, 138: 610-620. PMID: 35907197, DOI: 10.3171/2022.5.jns212761.Peer-Reviewed Original ResearchConceptsWeeks of biopsyOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingNational Cancer DatabaseInitiation of radiotherapyKaplan-Meier methodWorse overall survivalWilcoxon rank sum testEffects of confoundersRank sum testUnresected diseaseAdjuvant radiotherapyConcurrent chemotherapyMedian intervalMultivariable analysisRadiotherapy delayCancer DatabaseClinical dataBiopsyPatientsLate initiationAggressive natureRadiotherapyPotential association
2021
Testicular Cancer Radiotherapy
Mahal A, Yu J. Testicular Cancer Radiotherapy. Practical Guides In Radiation Oncology 2021, 255-299. DOI: 10.1007/978-3-030-65137-4_12.Peer-Reviewed Original ResearchNonseminoma germ cell tumorsLymph node contouringExcellent survival outcomesGerm cell tumorsSequelae of radiotherapyTreatment planning considerationsDose reduction strategiesPrognostic indicators of relapseIndicator of relapseFollow-up protocolModern radiotherapyRadiotherapy managementRadiotherapy fieldGenitourinary malignanciesCell tumorsSurvival outcomesPrognostic indicatorReview epidemiologyTesticular cancerRadiation treatmentRadiotherapyNational guidelinesBony landmarksAnatomical fieldTreatment
2020
Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact
Xu X, Soulos PR, Herrin J, Wang S, Pollack CE, Evans SB, Yu JB, Gross CP. Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact. Health Services Research 2020, 56: 497-506. PMID: 33070305, PMCID: PMC8143683, DOI: 10.1111/1475-6773.13572.Peer-Reviewed Original ResearchConceptsPhysician peer groupsWhole breast irradiationCF-WBIRisk-adjusted ratesBreast radiotherapyPractice patternsLow useChronic Conditions Data WarehouseDistinct practice patternsPatients' clinical characteristicsSetting of radiotherapyAdjuvant breast radiotherapyYears of ageDistinct trajectoriesImportant cost implicationsHigher useAdjuvant radiotherapyClinical characteristicsEligible womenBreast cancerCost implicationsLatent class growth analysisService beneficiariesMedicare programRadiotherapyTrends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-freeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteria
2019
Predictors of Toxicity from Stereotactic Body Radiotherapy (SBRT) for Lung Tumors Ultra-Central or Central to Heart, Esophagus, or Proximal Bronchial Tree
Chang E, Decker R, Hu X, Yu J, Gross C, Lester-Coll N. Predictors of Toxicity from Stereotactic Body Radiotherapy (SBRT) for Lung Tumors Ultra-Central or Central to Heart, Esophagus, or Proximal Bronchial Tree. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e499-e500. DOI: 10.1016/j.ijrobp.2019.06.1413.Peer-Reviewed Original ResearchAbandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.
Xu X, Soulos P, Herrin J, Wang S, Pollack C, Evans S, Gross C, Yu J. Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care. Journal Of Clinical Oncology 2019, 37: 531-531. DOI: 10.1200/jco.2019.37.15_suppl.531.Peer-Reviewed Original ResearchPhysician peer groupsBreast cancer careAdjuvant radiotherapyCancer careHigher useNational Medicare claimsPatient risk factorsDistinct trajectoriesYears of ageLow useDifferent baseline levelsRisk-adjusted ratesPatient cohortRisk factorsBreast cancerCost implicationsMedicare claimsBaseline levelsRadiotherapyMedicare perspectiveCFRTCurve analysisPhysiciansPatientsLatent growth curve analysisP69 Impact of Radiotherapy and Stereotactic Radiosurgery on Survival for Children and Adolescents: a Retrospective Population-based Study
Mahal A, Yu J. P69 Impact of Radiotherapy and Stereotactic Radiosurgery on Survival for Children and Adolescents: a Retrospective Population-based Study. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e48. DOI: 10.1016/s0360-3016(19)30519-x.Peer-Reviewed Original ResearchP78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample
Jairam V, Lee V, Park H, Thomas C, Melnick E, Gross C, Presley C, Adelson K, Yu J. P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e51-e52. DOI: 10.1016/s0360-3016(19)30528-0.Peer-Reviewed Original ResearchP28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer
Yang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.Peer-Reviewed Original ResearchRadiation Therapy for Renal Cell Carcinoma
Choi R, Yu J. Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer 2019, 3: 1-6. DOI: 10.3233/kca-180040.Peer-Reviewed Original ResearchRenal cell carcinomaTreatment of renal cell carcinomaStereotactic ablative radiotherapyRadiation therapyCell carcinomaAdjuvant treatment of renal cell carcinomaAblative radiotherapyAdjuvant treatmentTreatment optionsHigh dosesTherapyCarcinomaTargets of diseaseTreatmentRT’s roleRadiotherapyCancerDoseUnderutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer
Wang C, Raldow A, Nickols N, Nguyen P, Spratt D, Dess R, Yu J, King C, Chu F, Chamie K, Litwin M, Saigal C, Reiter R, Liu S, Rettig M, Chang A, Steinberg M, Kupelian P, Kishan A. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology 2019, 4: 327-330. PMID: 31411981, DOI: 10.1016/j.euo.2019.01.006.Peer-Reviewed Original ResearchConceptsConcomitant androgen deprivation therapyAndrogen deprivation therapyExternal beam radiotherapyDefinitive external beam radiotherapyHigh-grade prostate cancerGleason grade groupProstate cancerBeam radiotherapyDeprivation therapyGG 4NHW menDuration of androgen deprivation therapyAA menPopulation-based retrospective studyProstate cancer patientsMultiple randomized trialsNon-HispanicInverse probability treatmentSurvival benefitNon-Hispanic white menRetrospective studyRandomized trialsGrade groupRadiotherapyProbability treatment
2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Mahal B, Chen Y, Sethi R, Padilla O, Yang D, Chavez J, Muralidhar V, Hu J, Feng F, Hoffman K, Martin N, Spratt D, Yu J, Orio P, Nguyen P. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer 2017, 124: 1141-1149. PMID: 29231964, DOI: 10.1002/cncr.31190.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyProstate stereotactic body radiotherapyNational Cancer Data BaseLocalized prostate cancerShort-term efficacyProstate cancerTreated with definitive external beam radiotherapyDefinitive external beam radiotherapyDefinitive stereotactic body radiotherapyLong-term clinical implicationsFavorable disease characteristicsExternal beam radiotherapyAssociated with increased adjusted oddsMultivariate logistic regressionAcademic treatment centerAffluent zip codesBeam radiotherapyTreatment optionsDisease characteristicsRadiotherapyAdjusted oddsTreatment decisionsWhite raceYounger ageJoinpoint regressionPoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery.
Yu J, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery. Oncology 2017, 31: 830-2, 835. PMID: 29179251.Peer-Reviewed Original Research(P040) A Prospective Pilot Study of PSA Levels During Post-Operative Prostate-Bed Only Salvage Radiotherapy as A Predictor of Treatment Response
Yang D, Dosoretz A, Yu J. (P040) A Prospective Pilot Study of PSA Levels During Post-Operative Prostate-Bed Only Salvage Radiotherapy as A Predictor of Treatment Response. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e26. DOI: 10.1016/j.ijrobp.2017.02.135.Peer-Reviewed Original ResearchTrends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.
Mahal B, Chen Y, Muralidhar V, Yang D, Mahal A, Yu J, Orio P, Nguyen P. Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study. Journal Of Clinical Oncology 2017, 35: e545-e545. DOI: 10.1200/jco.2017.35.6_suppl.e545.Peer-Reviewed Original ResearchStereotactic body radiotherapyLocalized prostate cancerNational Cancer Data BaseGrade prostate cancerProstate cancerLow-risk disease featuresNational Cancer Database studyExternal beam radiotherapyLong-term efficacyMultivariate logistic regressionBeam radiotherapyRadiotherapy useTherapy optionsClinical factorsMultivariable adjustmentHazard ratioAcademic centersDisease characteristicsRadiotherapyDisease featuresProstateDatabase studyCancerPatientsHigher stage
2015
Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer.
Wang E, Corso C, Park H, Chen A, Kim A, Wilson L, Decker R, Yu J. Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer. Journal Of Clinical Oncology 2015, 33: 7538-7538. DOI: 10.1200/jco.2015.33.15_suppl.7538.Peer-Reviewed Original Research80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY
Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY. Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.Peer-Reviewed Original ResearchChange in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas
Jairam V, Rutter C, Yu J, Bindra R. Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. Journal Of Radiation Oncology 2015, 4: 163-167. DOI: 10.1007/s13566-015-0193-8.Peer-Reviewed Original ResearchAdjuvant chemotherapyAnaplastic astrocytomaRT volumeAnaplastic gliomasGlioma patientsMaximal responseAnaplastic glioma patientsRadiotherapy treatment volumesStable diseaseSalvage radiotherapyPathologic factorsHospital recordsChemotherapyPatientsIndependent sample t-testRadiotherapyTarget volumePercentage changeVolumetric reductionTreatment volumeSample t-testProgressionT-testGliomasSalvage